In Brief
This article was originally published in The Tan Sheet
Executive Summary
Prop 65 amendment would allow violation fixes; Valeant leapfrogs Merz in Obagi bid; ChromaDex sales up, profits down; TPSAC discusses modified risk tobacco application process; FDA clarifies FSMA registration suspension; AHPA recommends improvements to NIH LiverTox database; more In Brief.